Affordable Access

deepdyve-link
Publisher Website

COVID-19: Way Forward With Serosurveillance Without Overemphasizing Neutralizing Antibodies.

Authors
  • Krsak, Martin1
  • Henao-Martínez, Andrés F1
  • Franco-Paredes, Carlos1, 2
  • 1 Division of Infectious Diseases, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • 2 Instituto Nacional de Salud, Hospital Infantil de México, Federico Gomez, México City, México.
Type
Published Article
Journal
Viral Immunology
Publisher
Mary Ann Liebert
Publication Date
Apr 01, 2021
Volume
34
Issue
3
Pages
130–133
Identifiers
DOI: 10.1089/vim.2020.0246
PMID: 33181055
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Serosurveillance of coronavirus disease 2019 (COVID-19) is lagging due to concerns regarding testing performance and interpretation of what represents protective immunity. The scientific community has pointed out concerns related to suboptimal performance of certain tests, although a selection of tests with sensitivity and specificity of >99% is available. Neutralizing antibodies represent a generally accepted surrogate marker of immunological protection against viral infections. In COVID-19, we argue that focusing only on neutralizing antibodies may not be necessary and that evidence of spontaneous clearance of COVID-19 may be a reliable surrogate marker of individuals' immune competency toward future reinfections (regardless of its mechanism) for a period of time. Furthermore, current polymerase chain reaction testing lacks the ability to determine the duration of transmissibility, thus alternatives for direct testing of replicating virus are needed. Broadly applied viable virus testing together with serosurveillance will help reopen the economy with more precision and speed, and help guide isolation, quarantine, and cohorting protocols in conglomerate settings such as correctional facilities, nursing facilities, schools, and long-distance travel.

Report this publication

Statistics

Seen <100 times